Luke Riggan

Luke Riggan

Auto-generated profile, based on publicly available information

Luke Riggan

ImmunoVec, Los Angeles, CA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2023 in Blood
Verified
Journal Article
Open access
PDF file
RWRyan L. Wong
Ryan L. Wong
SSSarah Sackey
Sarah Sackey
DBDevin Brown
Devin Brown
SSShantha Senadheera
Shantha Senadheera
KMKatelyn Masiuk
Katelyn Masiuk
DKDonald Kohn
Donald Kohn
X-linked chronic granulomatous disease (X-CGD) is a primary immunodeficiency caused by mutations in the CYBB gene, resulting in the inability of phagocytic cells to eliminate infections. To design a lentiviral vector (LV) capable of recapitulating the endogenous regulation and expression of CYBB, a bioinformatics-guided approach was used to elucidate the cognate enhancer elements regulating the native CYBB gene. Using this approach, we analyzed a 600-kilobase topologically associated domain of the CYBB gene and identified endogenous enhancer elements to supplement the CYBB promoter to develop MyeloVec, a physiologically regulated LV for the treatment of X-CGD. When compared with an LV currently in clinical trials for X-CGD, MyeloVec showed improved expression, superior gene transfer to hematopoietic stem and progenitor cells (HSPCs), corrected an X-CGD mouse model leading to complete protection against Burkholderia cepacia infection, and restored healthy donor levels of antimicrobial oxidase activity in neutrophils derived from HSPCs from patients with X-CGD. Our findings validate the bioinformatics-guided design approach and have yielded a novel LV with clinical promise for the treatment of X-CGD.

22 April 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
MCMandy I. Cheng
Mandy I. Cheng
LRLuke Riggan
Luke Riggan
JLJoey H. Li
Joey H. Li
RTRana Yakhshi Tafti
Rana Yakhshi Tafti
SCScott Chin
Scott Chin
MSMaureen A. Su
Maureen A. Su
Viral infection outcomes are sex-biased, with males generally more susceptible than females. Paradoxically, the numbers of anti-viral natural killer (NK) cells are increased in males compared to females. Using samples from mice and humans, we demonstrate that while numbers of male NK cells are increased compared to females, they display impaired production of the anti-viral cytokine IFN-γ. These sex differences were not due solely to divergent levels of gonadal hormones, since these differences persisted in gonadectomized mice. Instead, these differences can be attributed to lower male expression of X-linked Kdm6a (UTX), an epigenetic regulator which escapes X inactivation in female NK cells. NK cell-specific UTX deletion in females phenocopied multiple features of male NK cells, which include increased numbers and reduced IFN-γ production. Integrative ATAC-seq and RNA-seq analysis revealed a critical role for UTX in the regulation of chromatin accessibility and gene expression at loci important in NK cell homeostasis and effector function. Consequently, NK cell-intrinsic UTX levels are critical for optimal anti-viral immunity, since mice with NK cell-intrinsic UTX deficiency show increased lethality to mouse cytomegalovirus (MCMV) challenge. Taken together, these data implicate UTX as a critical molecular determinant of NK cell sex differences and suggest enhancing UTX function as a new strategy to boost endogenous NK cell anti-viral responses.

3 April 2023
Verified
Other
Open access
MNMichael D. Nyquist
Michael D. Nyquist
ACAlexandra Corella
Alexandra Corella
JBJohn Burns
John Burns
ICIlsa Coleman
Ilsa Coleman
SGShuai Gao
Shuai Gao
EMElahe Mostaghel
Elahe Mostaghel
Fig S1. Androgen Mediated Growth Suppression in LnCaP

3 April 2023
Verified
Other
Open access
MNMichael D. Nyquist
Michael D. Nyquist
ACAlexandra Corella
Alexandra Corella
JBJohn Burns
John Burns
ICIlsa Coleman
Ilsa Coleman
SGShuai Gao
Shuai Gao
EMElahe Mostaghel
Elahe Mostaghel
Fig S2. SLC35F2 Expression Determines Sensitivity to YM155

3 April 2023
Verified
Other
Open access
MNMichael D. Nyquist
Michael D. Nyquist
ACAlexandra Corella
Alexandra Corella
JBJohn Burns
John Burns
ICIlsa Coleman
Ilsa Coleman
SGShuai Gao
Shuai Gao
EMElahe Mostaghel
Elahe Mostaghel
Fig S3. Tumor Androgen Levels Correlate with SLC35F2 Expression

3 April 2023
Verified
Other
Open access
MNMichael D. Nyquist
Michael D. Nyquist
ACAlexandra Corella
Alexandra Corella
JBJohn Burns
John Burns
ICIlsa Coleman
Ilsa Coleman
SGShuai Gao
Shuai Gao
EMElahe Mostaghel
Elahe Mostaghel
Correlation of tumor androgen levels with SLC35F2 transcript expression in PDX models